ISSN 3105-6741(Print)
ISSN 3105-675X(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3105-6741(Print)
ISSN 3105-675X(Online)

CODEN:LYYAA3
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社(CAS)
DOI前缀:
https://doi.org/10.66106/lyyaa3
国图集团 CIBTC
进口备案刊号:G015Z125

索引 检索 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
Wanfang Data(万方数据,中国,更新中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)
Enterscholar(恩特学术)

规划申请
Scopus 爱思唯尔·斯高帕斯(荷兰)

SinoMed 中国生物医学文献服务系统
DOAJ 开放获取期刊目录(瑞典)
PubMed 医学文摘数据库(美国)
PubMed Central 医学全文数据(美国)
EMBASE 爱思唯尔·医学文摘(荷兰)
EBSCO 学术文献数据库(美国)
OAJ 全球OA期刊索引(中国)

CABI 国际农业与生物科学中心(英国)
ProQuest 科睿唯安(美国)
Research4Life 世界卫生组织数据库


武汉办事处
主任 库盛娟
电话 +86 027-8860 7188
邮箱 gjqk@qikan999.com
微信 qikan7188
地址 武汉市武昌东湖路181号
邮编 430077
Editing and Publishing
Macau Sino-Foreign Medical Publishing Limited(MSFMP)
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://lcyyyj.scionline2025.com

  往期阅览 · All Issues-> 2025年 · 2025  
临床用药研究2025年第1卷第2期第14-24页,pISSN 3105-6741、eISSN 3105-675X 发布者:Quest Press 发布日期:2026/1/11
Open Access 浏览294

 

常规疗法联合胸腺五肽干预肺结核合并糖尿病患者免疫水平的 Meta 分析


胡建锋,刘啸天,姚名颜,王亮

1.南昌市红谷滩区妇幼保健院,江西南昌,330038 2.湖南中医药大学,湖南长沙,410208 3.南昌市新建区疾病预防控制中心,江西南昌,330199 4.桂林医科大学,广西桂林,541000

摘要:目的:通过Meta分析方法探讨常规疗法结合胸腺五肽对肺结核合并糖尿病(Tuberculosiscombinedwithdiabetes,PTB-DM)患者免疫功能的影响。方法:基于PRISMA规范(PreferredReportingItemsforSystematicReviewsandMeta-Analyses),检索8个中英文数据库(自建库至2025年7月13日),筛选出符合条件的观察性研究。使用Stata18.0软件进行数据分析,并采用固定/随机效应模型计算合并效应值获取关于常规疗法联合胸腺五肽干预肺结核合并糖尿病患者免疫水平的临床研究,文献语言限定为中文/英文,提取符合研究要求的文献数据。结果:(1)共纳入11篇符合要求的文献数据(均为中文文献),共纳入1037例患者(常规疗法联合胸腺五肽观察组520例、常规疗法对照组517例)。(2)观察组治愈率高于对照组(OR=2.35,95%CI:1.97-2.81,P<0.05),不同方法治愈率从高到低依次为:常规疗法联合胸腺五肽(OR=2.35)。(3)观察组有效率高于对照组(OR=3.81,95%CI:3.00-4.83,P<0.05)。(4)观察组CD3+水平显著高于对照组(OR=69.97vs53.77),CD4+/CD8+比值显著改善(OR=1.4vs1.2),CD4+、CD8+等免疫指标均优于对照组。结论:常规疗法联合胸腺五肽干预肺结核合并糖尿病患者免疫水平,相比单纯的常规疗法治愈能更好地改善PTB-DM患者的临床治愈率和有效率,联合方法治疗的患者的免疫功能都有效提升,但不同方法的具体优势尚需进一步探究。

关健词:常规疗法;胸腺五肽;肺结核;糖尿病;免疫水平
Meta-analysis of immune levels in patients with pulmonary tuberculosis complicated with diabetes mellitus intervened by conventional therapy combined with thymic pentapeptide

Jianfeng Hu,Xiaotian Liu,Mingyan Yao,Liang Wang

1.Honggutan District Maternal and Child Health Hospital,Nanchang City,Jiangxi,330038 2.Hunan University of Chinese Medicine,Changsha,Hunan,410208 3.Xinjian District Center for Disease Control and Prevention,Nanchang City,Jiangxi,330199 4. Guilin Medical University,Guilin,Guangxi,541000

Abstract:Objective:To explore the effect of conventional therapy combined with thymic pentapeptide on the immune function of patients with pulmonary tuberculosis complicated with diabetes mellitus(PTB-DM)through Meta-analysis. Method:Based on the PRISMA guidelines,multiple Chinese and English databases(from the establishment of the databases to July 13,2025)were retrieved,and observational studies that met the criteria were screened out. Data analysis was conducted using Stata 18.0 software,and the combined effect values were calculated using the fixed/random effects model to obtain clinical studies on the intervention of immune levels in patients with pulmonary tuberculosis complicated with diabetes by conventional therapy combined with thymic pentapeptide. The language of the literature was limited to Chinese or English. Results of extracting literature data that met the research requirements:(1)A total of 11 literature data that met the requirements were included (all in Chinese),and a total of 1,037 patients were included (520 cases in the conventional therapy combined with thymic pentappeptide observation group and 517 cases in the conventional therapy control group).(2)The cure rate of the observation group was higher than that of the control group (OR=2.35,95%CI:1.97-2.81,P < 0.05). The cure rates of different methods from high to low were:conventional therapy combined with thymic pentapeptide (OR=2.35).(3)The effective rate of the observation group was higher than that of the control group (OR=3.81,95%CI:3.00-4.83,P < 0.05).(4)The level of CD3+ in the observation group was significantly higher than that in the control group (OR=69.97 vs 53.77),the ratio of CD4+/CD8+ was significantly improved (OR=1.4 vs 1.2),and the immune indicators such as CD4+ and CD8+ were all better than those in the control group. Conclusion:Conventional therapy combined with thymic pentapeptide intervention on the immune level of patients with pulmonary tuberculosis complicated with diabetes can better improve the clinical cure rate and effective rate of patients with PTB-DM compared with the cure of conventional therapy alone. The immune function of patients treated by the combined method has been effectively enhanced,but the specific advantages of different methods still need to be further explored.


Keywords : Conventional therapy;Thymic pentapeptide;Tuberculosis;Diabetes;Immune level


参考文献
[1]曹素珍,陆春芬,赵小峰.胰岛素、常规抗结核及胸腺五肽联合治疗初治菌阳肺结核合并糖尿病的效果[J].现代医学与健康研究电子杂志,2019,3(7):35-36.
[2]陈虹.胸腺五肽治疗66例糖尿病并发肺结核患者观察[J].中国医药指南,2012,10(10):152-153.
[3]郭文霞.胸腺五肽对肺结核合并糖尿病免疫状态的影响[J].临床军医杂志,2015,43(3):314-315.
[4]凌应冰,卢艳春,谢鸿恩.胸腺五肽治疗肺结核合并糖尿病的疗效评价[J].实用中西医结合临床,2018,18(6):14-15.
[5]马艳丽.肺结核合并糖尿病应用胸腺五肽辅助治疗的效果观察[J].基层医学论坛,2020,24(8):1092-1094.
[6]南勇,占春华.胸腺五肽联合化疗方案治疗初治肺结核合并糖尿病的临床价值分析[J].中国社区医师,2018,34(10):72-73.
[7]任万良,来力伟,王科文.胸腺五肽联合胰岛素辅助治疗肺结核合并2型糖尿病的临床效果[J].临床医学研究与实践,2025,10(3):71-74.
[8]王钧,任瑞华,李香兰,等.肺结核合并糖尿病患者应用胸腺五肽辅助治疗效果观察[J].河北医药,2016,38(15):2283-2285.
[9]杨丽.胸腺五肽联合短程化疗治疗肺结核伴糖尿病患者的效果分析[J].中外医学研究,2016,14(22):18-20.
[10]张国栋.胸腺五肽联合化疗方案治疗初治肺结核合并糖尿病的效果及安全性[J].临床医学,2018,38(7):115-117.
[11]钟殿海.胸腺五肽对肺结核合并糖尿病免疫状态的影响分析[J].糖尿病新世界,2015,15(15):59-61.
[12]凌应冰.胸膜五肽辅助治疗肺结核合并糖尿病临床研究[J].中国卫生标准管理,2020,11(06):85-87.
[13]黄晓磊,宋晓东,张娜.胸腺五肽联合化疗方案治疗初治肺结核合并糖尿病的临床疗效分析[J].中国医药指南,2018,16(29):89-90.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Macau Sino-Foreign Medical Publishing Ltd.(MSFMP)
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The MSFMP publishes articles under the following open access license.
Quest Press
is a member of the following organizations.